Within the time period assessed, 179 reports of alopecia were reported for tirzapetide, 199 reports for semaglutide (Ozempic), and fewer reports for other GLP-1 receptor agonists (GLP-1 RAs)
BPC-157 specifically is not approved by the FDA or EMA, and a 2023 FDA Category 2 designation restricts injectable compounding in the United States
Patients routinely achieve double-digit percentage reductions in body fat when taking them
Clinical Evidence on Tirzepatide Weight Loss Results Large randomized trials involving over 2,500 participants demonstrated that tirzepatide at maximum doses produced average weight losses ranging from 20% to 22% of baseline body weight over 68 weeks of treatmentsignificantly higher than placebo and comparable to or exceeding earlier single-agent GLP-1 therapies
In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients
